Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05124457 · ClinicalTrials.gov registry record · Phase 2

DETERMINE: Detemir vs NPH

A Phase 2 study of Diabetes Mellitus, Type 2 and Gestational Diabetes, sponsored by University of California, Los Angeles.

Recruiting
Registry status
Phase 2
Development phase
336
Enrollment target
1
Study location

NCT05124457: Recruiting Phase 2 study of Diabetes Mellitus, Type 2 and Gestational Diabetes, sponsored by University of California, Los Angeles.

NCT05124457 is a Phase 2 study of Diabetes Mellitus, Type 2 and Gestational Diabetes that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 336 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05124457, a Phase 2 study of Diabetes Mellitus, Type 2 and Gestational Diabetes, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
Phase 2
Development phase
336 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to compare rates of neonatal hypoglycemia with maternal NPH vs determir use.

Primary Outcome

Rate (%) of neonatal hypoglycemia

Conditions Studied

Diabetes Mellitus, Type 2 Gestational Diabetes

Interventions

  • DRUG Insulin Detemir
  • DRUG Insulin NPH

Study Locations (1)

California

  • University of California, Los Angeles - Los Angeles

Trial Details

FieldValue
Enrollment Target 336 participants
Start Date 2022-02-01
Est. Completion 2025-06
Phase Phase 2
University of California, Los Angeles

897 total trials

What NCT05124457 shows while recruiting

NCT05124457 is an interventional study that assigns participants to a tested intervention. The registered 336 participants enrollment target is mid-sized for trials with a published cap, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (93% lower).

The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Insulin Detemir is the first listed.

NCT05124457 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05124457 about?

NCT05124457 is a clinical study titled "DETERMINE: Detemir vs NPH". The purpose of the study is to compare rates of neonatal hypoglycemia with maternal NPH vs determir use.

What is the current status of trial NCT05124457?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 336 participants. The study started on 2022-02-01. Estimated completion is 2025-06.

What conditions does trial NCT05124457 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Gestational Diabetes.

What interventions are being tested in trial NCT05124457?

The interventions under investigation include: Insulin Detemir (DRUG), Insulin NPH (DRUG).

Who is sponsoring clinical trial NCT05124457?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05124457 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05124457's enrollment target sits among peer trials

336 108th of 348 higher than 241 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03947385 · 336 participants · Phase 1

    Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

  • NCT03977207 · 336 participants · NA

    A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients

  • NCT04665206 · 336 participants · Phase 1

    Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

  • NCT05245500 · 336 participants · Phase 1

    Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05124457

Source: ClinicalTrials.gov NCT05124457, the US trial registry maintained by the National Library of Medicine. NCT05124457 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.